MedTrace Logo

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02260557 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-02-03

No results posted yet for this study

Summary

The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).

Conditions

  • Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

DRUG

Selexipag

Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily

DRUG

Placebo

Placebo matching selexipag 200 μg tablets to be administered orally twice daily

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Ralph Preiss, MD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-04-30
Completion
2015-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02260557 on ClinicalTrials.gov